Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies, today released its analysis of Quantum BioPharma Ltd.'s (NASDAQ: QNTM) continued progress across its innovative pipeline of treatments for brain disorders and alcohol health.» Mehr auf newsfilecorp.com
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302 Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302» Mehr auf globenewswire.com
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce its intention to declare a special dividend consisting of Contingent Value Rights (the “CVRs”) to be issued on a 1:1 basis to holders of the Company's Class B Subordinate Voting Shares.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Quantum BioPharma Aktie einen Umsatz von 0,00€ und ein Nettoeinkommen von −7,90 Mio€

(EUR)	März 2025	YOY
Umsatz	0,00	-
Bruttoeinkommen	−119,52k	-
Nettoeinkommen	−7,90 Mio	348,17%
EBITDA	−7,61 Mio	321,25%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+88,71 Mio€
Anzahl Aktien	2,91 Mio
52 Wochen-Hoch/Tief	+33,35€ - +2,35€
Dividenden	Nein
Beta	1,47
KGV (PE Ratio)	−1,91
KGWV (PEG Ratio)	+0,08
KBV (PB Ratio)	+6,94
KUV (PS Ratio)	0,00